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1684Objectives: Evidence is accumulating of adverse outcomes associated with transfusion of blood components.
If there are differences in perioperative transfusion rates in cardiac surgery, and what hospital factors may
contribute, requires further investigation.
Methods: Analysis of 42,743 adult patients who underwent 43,482 procedures from 2005 to 2011 at
25 Australian hospitals, according to the Australian and New Zealand Society of Cardiac and Thoracic Surgeons
Cardiac Surgery Database. Multiple logistic regression examined associations of patient and hospital
characteristics with transfusion of 1 red blood cell (RBC) unit; platelet (PLT), fresh frozen plasma (FFP),
and cryoprecipitate (CRYO) doses; and 5 RBC units, from surgery until hospital discharge.
Results: Procedures included 24,222 (55%) isolated coronary artery bypass grafts, 7299 (17%) isolated valve,
4714 (11%) coronary artery bypass graft and valve, and 7247 (17%) other procedures. After adjustment for
various patient and procedure characteristics, transfusion rates varied across hospitals for 1 RBC unit from
22% to 67%, 5 RBC units from 5% to 25%, 1 PLT dose from 11% to 39%, 1 FFP dose from 11% to
48% and 1 CRYO dose from 1% to 20%. Hospital characteristics, including state or territory, private versus
public, and teaching versus nonteaching, were not associated with variation in transfusion rates.
Conclusions: Variation in transfusion of all components and large volume RBC was identified, even after
adjustment for patient and procedural factors known to influence transfusion, and this was not explained by
hospital characteristics. (J Thorac Cardiovasc Surg 2014;147:1684-90)he Department of Epidemiology and Preventive Medicine,a Monash
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A substantial proportion of blood components worldwide
are issued to patients undergoing cardiac surgery. In
Australia this is the second most common surgical
indication for red blood cell (RBC) use; the largest single
indication for fresh frozen plasma (FFP), accounting for
approximately 15% of all plasma use; and the second
largest indication for platelet (PLT) transfusion after
hematology and oncology.1,2 Despite the significant use of
blood components by patients undergoing cardiac surgery,
the evidence to guide transfusion therapy is limited,
particularly for components other than RBCs. There have
been few studies on the optimal triggers for RBC
transfusion, and these have been mostly in other clinical
settings.3,4 Studies on the use of FFP and PLT in cardiac
surgery are also limited, with varying results regarding
outcomes.5-8
There is evidence of significant variation in the transfu-
sion rates of blood components in cardiac surgery between
institutions and individual clinicians,9-12 and this variation
has been shown to continue following publication ofgery c May 2014
Abbreviations and Acronyms
ANZSCTS ¼ Australian and New Zealand Society
of Cardiac and Thoracic Surgeons
CABG ¼ coronary artery bypass graft
CRYO ¼ cryoprecipitate
FFP ¼ fresh frozen plasma
PLT ¼ platelet
RBC ¼ red blood cell
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Mtransfusion practice guidelines.13 A previous small Austra-
lian survey conducted in 2004 reported substantial variation
in RBC use between institutions following cardiac
surgery.14 It is not known if these differences persist, if
this also applies to the use of non-RBC components, and
if hospital characteristics contribute to differences in
practice. In our study, we investigated if significant
variation exists in blood product use in cardiac surgery, after
adjusting for patient-related variables that might reasonably
influence the need for transfusion. We also investigated if
hospital characteristics account for variation in transfusion
rates after adjusting for patient-level characteristics.
METHODS
Patients
All cardiac surgery patients aged 18 years or older reported to the
Australian and New Zealand Society for Cardiac and Thoracic Surgery
(ANZSCTS) Cardiac Surgery Database, between January 1, 2005, and
December 31, 2011, from 25 Australian hospitals, were included in the
study. Not all 25 hospitals reported for the entire study duration; however,
once reporting commenced all consecutive cases were included.
During this period there were a total of 43,482 procedures recorded in
42,743 adult patients at the 25 hospitals. These included isolated coronary
artery bypass graft (CABG) in 24,222 (55%), isolated valve in 7299
(17%), CABG and valve in 4714 (11%), and other procedure in 7247
(17%). Procedures (n ¼ 147) in patients younger than age 18 years were
excluded.
ANZSCTS Cardiac Surgery Database
The ANZSCTS Cardiac Surgery Database prospectively collects
information on all adult patients undergoing cardiac surgery at
participating hospitals using a standardized data set and definitions,
including patient demographics, preoperative risk factors, preoperative
medications, intraoperative details, transfusion therapy received (including
number of units of RBCs, PLTs, FFP, and cryoprecipitate [CRYO]), length
of stay, complications, and patient outcomes.15
Statistical Methods
Summary statistics for continuous data are reported as mean and
standard deviation or median and interquartile range as appropriate, and
as number and percent for categorical variables.
Binary categorical variables for the outcomes of interest were created:
1 RBC unit, large-volume RBC transfusion (5 RBC units), low-
volume RBC transfusion (1 or 2 RBC units), 1 FFP adult equivalent
dose, 1 PLT adult equivalent dose, and 1 CRYO adult equivalent
dose. Logistic regression analyses explored the association between
covariates, including hospital site, and outcomes, using a backward
stepwise approach. Variables that were associated with the outcomes ofThe Journal of Thoracic and Carinterest with a P value<.25 were considered for the multiple logistic
regression models. Pearson’s correlation was used to assess variables for
potential colinearity, with the more clinically relevant variable selected
where present. Covariates considered for the models were those which
that reasonably influence a decision to transfuse and included hospital
site, patient age, sex, body mass index, peripheral or cerebrovascular
disease, prior myocardial infarction, diabetes, New York Heart Association
functional class, lung disease, infective endocarditis, preoperative
creatinine, medications (including antiplatelet agents within 5 days,
anticoagulants, and immunosuppressive therapy), previous cardiothoracic
procedure, procedure type and urgency, preoperative shock, and use of
intra-aortic balloon pump. Correlation of hospital-adjusted rates of RBC
versus PLT and RBC versus FFP were also assessed. Analysis was
performed on all procedures and repeated for first-time CABG only.
To explore the association of hospital-level characteristics and outcome,
variables for the type of institution (academic affiliation and private or
public) and in which area they were located, the median number of cardiac
procedures performed annually, and previous covariates were added in
multiple multilevel logistic regression models, where hospital site was
now modeled as a random effect.16
All analyses were performed using the statistical software packages
Stata 11.2 (Statacorp LP, College Station, Tex).RESULTS
Patient demographics, comorbidities, and surgical and
hospital characteristics for all procedures are shown in
Table 1. The total number of cardiac surgeries performed
at each hospital ranged from 312 to 4193 (median, 1327;
IQR, 669-2557) and the median annual number of cardiac
surgeries performed at each hospital ranged from 154 to
588 (median, 238; IQR, 164-353).
The most important patient characteristics associated
with RBC transfusion in multivariate analysis based on
effect size included patient age (odds ratio [OR], 1.1;
95% confidence interval [CI], 1.0-1.1), New York Heart
Association functional class II or greater heart failure
(class IV OR, 1.7; 95% CI, 1.5-1.9) procedure other than
isolated CABG or valve (OR, 2.2; 95% CI, 1.9-2.3),
previous cardiac surgery (OR, 1.3; 95% CI, 1.2-1.4), urgent
(OR, 2.9; 95% CI, 2.5-3.2) or emergency surgery (OR, 3.7;
95% CI, 2.1-6.5), and the use of acetylsalicylic acid
(OR, 1.2; 95% CI, 1.1-1.2) or clopidogrel (OR, 1.1; 95%
CI, 1.1-1.2) within 7 days before surgery.
The rate of transfusion, after adjusting for patient and
surgical characteristics, of any RBC unit ranged between
hospitals from 22% to 67%, 5 RBC units from 5% to
24%, 1 or 2 RBC units from 10% to 34%, 1 PLT dose
from 10% to 39%, 1 FFP dose from 10% to 44%, and
1 CRYO dose from 1% to 21%. The hospital-adjusted
rates of transfusion of RBC, PLTs, FFP, and CRYO for all
procedures are shown in Figure 1. Similar variation in
adjusted rates of blood product use was also present when
the analysis was limited to only isolated CABG procedures
with no history of previous cardiac surgery (Figure E1).
Hospital rates of RBC versus PLT transfusion and RBC
versus FFP transfusion after adjustment for patient and
surgical characteristics are shown in Figure 2.diovascular Surgery c Volume 147, Number 5 1685
TABLE 1. Patient, surgical, and hospital characteristics for all
procedures
Characteristic All procedures
Total number of procedures 43,482
Patient demographics
Age, y 66  13
Male gender 31,414 (72)
Body mass index 28.2  5.4
Prior myocardial infarction 16,652 (38)
Cerebrovascular disease 5027 (12)
Dialysis preoperative 752 (2)
Lung disease 5815 (13)
Congestive heart failure 10,153 (23)
Diabetes 12,344 (28)
Medications
Anticoagulants at time of surgery 8622 (20)
Acetylsalicylic acid within 7 d 21,655 (50)
Clopidogrel within 7 d 5292 (12)
Surgical
Previous cardiothoracic surgery 8320 (19)
Procedure type
Isolated coronary artery bypass graft 24,222 (55)
Isolated valve 7299 (17)
Other 11,961 (28)
Urgency more than elective 14,482 (34)
Cardiopulmonary bypass duration, min 113  56
Crossclamp time, min 82  42
Intra-aortic balloon pump 2305 (5)
Hospital level characteristics (n ¼ 25 hospitals)
Academic affiliation (n ¼ 18) 35,345 (81)
No academic affiliation (n ¼ 7) 8137 (19)
Public (n ¼ 19) 36,041 (83)
Private (n ¼ 6) 7441 (17)
State 1 (n ¼ 9) 23,082 (53)
State 2 (n ¼ 9) 13,573 (31)
Other (n ¼ 7) 6872 (16)
Values are presented as mean  standard deviation or n (%).
Perioperative Management McQuilten et al
P
MThe observed rates of transfusion of RBC, PLT, FFP,
and CRYO by hospital-level characteristics are shown in
Table 2. After adjustment for patient characteristics
(including patient and procedure characteristics) in the
multilevel regression analysis, none of the 4 hospital-level
characteristics was associated with the transfusion out-
comes examined (Table 3).DISCUSSION
This nationwide analysis of 43,529 cardiac surgical
procedures performed at 25 hospitals within Australia
demonstrated substantial variation in hospital rates of
transfusion of blood components, after adjusting for patient
and surgical characteristics, which was not accounted for by
the hospital characteristics examined. The finding of
variation in blood product use is consistent with a previous
Australian study and other international studies that have1686 The Journal of Thoracic and Cardiovascular Surdemonstrated variation in transfusion of RBCs,14 PLTs,
and plasma in cardiac surgery.9-12,17,18
Substantial variation in both low volume and large
volume RBC transfusion across the 25 institutions was
identified, and this variation persisted after adjusting for
patient and surgical characteristics that might reasonably
influence a decision to transfuse and limiting the analysis
to isolated CABG. It is not surprising that individual
clinician preference or institutional practice may influence
the decision for a low volume RBC transfusion during the
perioperative period. However, the requirement of large
volume transfusion also appears to be in part dependent
on institutional practice even after adjusting for patient
and surgical characteristics, including the need for
reoperation to control bleeding. Because we did not
examine rates of perioperative blood loss between sites, it
is not possible from our study to determine if the variation
in large volume transfusion is due to differences in bleeding
complications across sites or due to a difference in the
preferred approach to manage large volume blood loss.
However, another study17 that demonstrated variation in
rates of massive transfusion following cardiac surgery
found that perioperative bleeding was relatively consistent
between sites, whereas methods for managing this bleeding
was more subject to differences.
As observed for RBC transfusion, there was wide
variation in the use of FFP, PLT, and CRYO. Hospitals
that had higher use of RBCs also tended to have higher
transfusion rates of other blood products, and those with a
more restrictive use of RBCs had comparatively lower rates
of transfusion of other components.
Although there was considerable variation between
institutions in transfusion practice, this did not appear to
be attributable to hospital-level characteristics, including
if the hospital was private or public, had an academic
affiliation, or the median number of procedures performed
annually. Although differences were evident in observed
rates of transfusion between private and public hospitals
and also academic status, after adjusting for patient and
surgical characteristics, the association of these hospital-
level characteristics with transfusion did not persist. This
is in contrast to a study from the United States9 linking
perioperative RBC use to hospital academic status and
geographic region. Although Australia has a relatively
uniform health system, there are differences between state
jurisdictions in health service structures and the funding
of blood products, which may influence practice. However,
after adjusting for patient and surgical characteristics,
geographic location did not explain the variation in rates
of transfusion between institutions.
The finding of variation in transfusion practice in our
study, as in other studies, is important for a number of
reasons. There is increasing evidence from observational
studies of an association between RBC transfusion andgery c May 2014
FIGURE 1. Adjusted transfusion outcome rates for all procedures at 25 hospitals. CI, Confidence interval; RBC, red blood cell; PLT, platelet; FFP, fresh
frozen plasma; CRYO, cryoprecipitate.
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Madverse outcomes, including mortality (both short and
long-term survival), length of stay, multiorgan failure,
infection, and thrombosis.19-21 Due to ethical and
practical constraints, randomized controlled trials of
transfusion compared with nontransfusion in cardiac
surgery have not been performed. However, studies
comparing different transfusion strategies, including
restrictive or reduced transfusion triggers, have shown
comparable outcomes. A noninferiority randomized
controlled trial of 502 patients undergoing cardiac surgery
with cardiopulmonary bypass comparing a restrictive with
a more liberal transfusion strategy (maintaining a
hematocrit of 24% vs 30%) found comparable mortality
and morbidity outcomes.3 However, this was a single-
center study, used fresh nonleukoreduced RBCs, andThe Journal of Thoracic and Carincluded less than half of all eligible patients, so the
generalizability of the study findings are limited. Other
observational studies have demonstrated an association
between reduction in blood transfusion rates and improved
outcomes.22
There are even fewer data to guide transfusion
support with other blood components in cardiac surgery.
Transfusion of FFP has been associated with increased
mortality in cardiac surgery8; however, there are
conflicting findings on the association of PLT transfusions
with outcomes.5,23 Although studies have reported on use
of fibrinogen concentrate in cardiac surgery, the use of
CRYO has not been examined.24 The lack of evidence to
support transfusion decisions for blood components other
than RBCs may contribute to the observed variation indiovascular Surgery c Volume 147, Number 5 1687
FIGURE 2. Adjusted rates of platelet (PLT), fresh frozen plasma (FFP), and red blood cell (RBC) transfusion, by hospital.
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recently published national Perioperative Patient Blood
Management Guidelines,24 few recommendations or
practice points could be made for the use of other blood
components due to the lack of evidence. The marked
variation in blood product use in cardiac surgery, coupled
with limited evidence to inform practice, highlights the
requirement for future studies to assess the effect of blood
components on patient outcomes.
With the accumulating evidence of the association of
RBC transfusion with some adverse outcomes, the
increasing costs associated with transfusion and consider-
ation of preservation of limited blood supplies, it has been
proposed that RBC transfusion should be included as a
quality indicator in cardiac surgery.25 With an aging
population and advances in medical care, the demand for
blood products is expected to rise, placing further demands
on a limited resource. In addition, the cost of transfusion is
increasing, with reduced donor availability and measures to
minimize transfusion risks as contributing factors.26
Although reducing unnecessary transfusions is important,
there is likely to be a point, albeit as yet undefined, where
lowering the transfusion rate any further would pose risksTABLE 2. Frequency of blood product use, by hospital-level characteristi
Hospital characteristic Any RBC RBC (1-2 units)
Public 16,389 (46) 7812 (22)
Private 3047 (41) 1484 (20)
Academic affiliation
Yes 16,118 (46) 7671 (22)
No 3318 (41) 1625 (20)
State 1 10,231 (44) 4874 (21)
State 2 6387 (47) 2965 (22)
Other states 2818 (42) 1457 (22)
Values are presented as n (%). RBC, Red blood cell; PLT, platelet; FFP, fresh frozen plas
1688 The Journal of Thoracic and Cardiovascular Surfor patients. Therefore, when considering transfusion as a
quality indicator, it should be the rate of appropriate
transfusion, rather than the lowest transfusion rate, that is
the desired outcome.
It has been argued that wide variation in transfusion
practice is an indicator of excessive or inappropriate
transfusions.27 However substantial variation in practice is
also a pointer to an inadequate evidence base to guide
practice. In this setting, the optimal use of blood products
in cardiac surgery has not been well established and
therefore the ideal approach to change transfusion practice
and reduce variation is not clear.
Our study has demonstrated significant institutional
variation in transfusion practice within a relatively uniform
health system and with ready access to blood products.
However, neither patient, procedure, nor hospital-level
characteristics, including academic affiliation or the
hospital’s location, accounted for this variation. These
observed differences should be interpreted in light of the
limitations of the study. First, the ANZSCTS Cardiac
Surgery Database does not include preoperative or
intraoperative hemoglobin, hematocrit, platelet count, or
coagulation profile, nor does it collect information on thecs
RBC (5 units) PLT FFP CRYO
4595 (13) 8649 (24) 8365 (23) 3180 (9)
741 (10) 1382 (19) 1389 (19) 450 (6)
4539 (13) 8571 (24) 8266 (23) 3171 (9)
797 (10) 1460 (18) 1488 (18) 459 (6)
2844 (12) 5297 (23) 4716 (20) 2188 (10)
1808 (13) 3234 (24) 3472 (26) 1229 (9)
684 (10) 1500 (22) 1566 (23) 213 (3)
ma; CRYO, cryoprecipitate.
gery c May 2014
TABLE 3. Odds ratio and 95% confidence intervals of association of hospital-level characteristics and transfusion outcomes for all procedures*
Hospital characteristic Any RBC RBC 1-2 units RBC 5 units PLT FFP CRYO
Public 1.0 1.0 1.0 1.0 1.0 1.0
Private 0.8 (0.2-2.9) 0.9 (0.4-1.8) 0.8 (0.2-2.3) 1.7 (0.7-4.3) 0.9 (0.3-3.1) 2.2 (0.3-17)
Academic affiliation
Yes 1.0 1.0 1.0 1.0 1.0 1.0
No 1.1 (0.4-4.5) 1.0 (0.5-2.0) 1.1 (0.3-3.3) 0.5 (0.2-1.2) 0.8 (0.2-2.6) 0.5 (0.1-3.5)
State 1 1.0 1.0 1.0 1.0 1.0 1.0
State 2 1.4 (0.8-2.4) 1.2 (0.8-1.6) 1.1 (0.7-1.9) 1.1 (0.7-1.6) 1.6 (0.9-2.6) 1.3 (0.6-3.4)
Other states 1.0 (0.6-1.8) 1.0 (0.7-1.5) 0.7 (0.4-1.2) 1.1 (0.6-1.7) 1.2 (0.6-2.3) 0.5 (0.2-1.3)
Median number 0.9 (0.9-1.0) 0.9 (0.9-1.0) 0.9 (0.9-1.0) 0.9 (0.9-1.0) 0.9 (0.9-1.0) 0.9 (0.9-1.0)
RBC, Red blood cell; PLT, platelet; FFP, fresh frozen plasma; CRYO, cryoprecipitate. *Odds ratio (95% confidence interval) are frommultiple multilevel logistic regression with
assignment of random effects for each hospital.
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Muse of autologous blood. Therefore, the rates of transfusion
could not be adjusted for these parameters in the
multivariate analysis. Second, although the quality of the
ANZSCTS data, including accuracy and completeness,
has been validated with an external quality audit program,
this has not included transfused blood components.15
Although we have established a generally high degree of
accuracy of our data sources, it is possible that a small
part of the institutional variation observed might be
attributed to the way in which data on transfused blood
components is collected or recorded.
CONCLUSIONS
These findings from a large and prospectively collected
cardiac surgery database demonstrate wide variation in
transfusion practice not accounted for by patient or
hospital-level characteristics. Many areas remain where
the evidence base to inform the use of blood products in
cardiac surgery is lacking. Further clinical studies and
formal evaluation of the effect of patient blood management
programs, rates of transfusion, and patient outcomes, is
warranted.
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FIGURE E1. Adjusted transfusion outcome rates for primary coronary artery bypass graft only for 25 hospitals. CI, Confidence interval; RBC, red blood
cell; PLT, platelet; FFP, fresh frozen plasma; CRYO, cryoprecipitate.
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